http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10174311-B2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b1a2803c09ca1bd4d531063f1df481ff
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16621
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-401
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2469-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16634
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56983
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56994
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0208
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0225
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56911
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-098
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56916
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-285
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56927
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5695
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-285
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005
filingDate 2016-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2019-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41c8a760a734c3876da018368f721e8a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b644c17bc3f095bfd79e3ccf8569b999
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0696b15650040437a4f63fd7dd00a32b
publicationDate 2019-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-10174311-B2
titleOfInvention Compositions and methods for immunodominant antigens
abstract Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens ( Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis , human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum , and Vaccinia virus ) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.
priorityDate 2006-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6032
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395099

Total number of triples: 62.